Edition:
United Kingdom

Tandem Diabetes Care Inc (TNDM.OQ)

TNDM.OQ on NASDAQ Stock Exchange Global Market

2.59USD
4:19pm GMT
Change (% chg)

$0.03 (+1.17%)
Prev Close
$2.56
Open
$2.57
Day's High
$2.65
Day's Low
$2.53
Volume
11,450
Avg. Vol
89,584
52-wk High
$30.00
52-wk Low
$2.15

Chart for

About

Tandem Diabetes Care, Inc. is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System... (more)

Overall

Beta: 0.35
Market Cap(Mil.): $41.19
Shares Outstanding(Mil.): 50.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.01 10.62
ROE: -- 16.85 14.20

BRIEF-Tandem Diabetes Care reports Q3 sales of $27 million

* Tandem Diabetes Care reports third quarter 2017 financial results

26 Oct 2017

BRIEF-‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost

* ‍Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers​

24 Oct 2017

BRIEF-Empery Asset Management reports 5.63 pct passive stake in Tandem Diabetes Care

* Empery Asset Management Lp reports 5.63 pct passive stake in Tandem Diabetes Care Inc as of Oct 13 - SEC filing‍​ Source text: (http://bit.ly/2hSFBfg) Further company coverage:

20 Oct 2017

BRIEF-Tandem Diabetes Care sees Q3 sales of about $26.5 mln to $27.5 mln

* Sees Q3 sales about $26.5 million to $27.5 million - sec filing

13 Oct 2017

BRIEF-Tandem Diabetes Care announces proposed public offering of common stock

* Tandem Diabetes Care announces proposed underwritten public offering of common stock, Series A warrants and Series B warrants Source text for Eikon: Further company coverage:

12 Oct 2017

BRIEF-Tandem Diabetes Care‍ shareholders approv reverse stock split

* Tandem Diabetes Care Inc- ‍ shareholders subsequently approved reverse stock split at a ratio of 1-for-10​ Source text for Eikon: Further company coverage:

09 Oct 2017

BRIEF-Tandem Diabetes Care announces FDA approval, launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

* Tandem Diabetes care announces FDA approval and launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

28 Aug 2017

BRIEF-Tandem Diabetes Care announces issuance of patent related to remote bolus feature for medical infusion pumps

* Tandem Diabetes Care announces issuance of patent related to remote bolus feature for medical infusion pumps Source text for Eikon: Further company coverage:

24 Aug 2017

BRIEF-Tandem Diabetes Care begins enrollment for 1st touchscreen insulin pump with PGLS

* Tandem Diabetes Care begins enrollment in pivotal trial for first touchscreen insulin pump with predictive low glucose suspend (PLGS)

15 Aug 2017

BRIEF-Tandem Diabetes Care Q2 net loss per share $0.44

* Tandem Diabetes Care reports second quarter 2017 financial results

27 Jul 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.03 -0.43
Roche Holding Ltd. (ROG.S) CHF246.00 +1.90
Roche Holding Ltd. (RO.S) CHF246.80 +3.40
Insulet Corporation (PODD.OQ) $69.25 +0.80

Earnings vs. Estimates